The idiopathic pulmonary fibrosis market size has grown strongly in recent years. It will grow from $4.15 billion in 2024 to $4.39 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to increasing aging population, limited treatment options, rising disease awareness, healthcare infrastructure development.
The idiopathic pulmonary fibrosis market size is expected to see strong growth in the next few years. It will grow to $5.74 billion in 2029 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to expanded research and development, precision medicine approach, increasing disease incidence, advancements in biomarker development, government initiatives and funding. Major trends in the forecast period include advancements in diagnostic techniques, emergence of targeted therapies, telemedicine and remote monitoring, combination therapies, advancements in lung transplantation.
The idiopathic pulmonary fibrosis market is poised for growth, primarily driven by the increasing prevalence of fibrotic diseases. These conditions, marked by the abnormal accumulation of fibrous connective tissue in various organs, receive treatment through idiopathic pulmonary fibrosis (IPF) drugs targeting fibrosis-related signaling pathways. Notably, the American Lung Association reported in December 2022 that around 207,000 individuals in the United States were affected, with approximately 58,000 new IPF cases diagnosed annually. This condition, more prevalent in men and predominantly affecting those aged over 50, underscores the significant role of escalating fibrotic diseases in driving the idiopathic pulmonary fibrosis market.
The growing geriatric population is anticipated to drive the expansion of the idiopathic pulmonary fibrosis (IPF) market in the future. The geriatric population consists of elderly individuals within a specific society or community. Aging is linked to both structural and functional changes in the lungs, which increase the vulnerability of older adults to respiratory diseases like IPF. This age-related susceptibility contributes to the rising demand for IPF treatments. For example, in October 2022, the World Health Organization, a specialized health agency based in the US, reported that by 2030, 1 in 6 people globally will be aged 60 or older, with the number of individuals in this age group expected to reach 2.1 billion by 2050. Consequently, the increasing geriatric population is propelling the growth of the idiopathic pulmonary fibrosis market.
A notable trend gaining momentum in the idiopathic pulmonary fibrosis market is product innovation. Major companies in the industry are placing emphasis on developing innovative products to strengthen their market positions and gain a competitive advantage. For instance, in May 2022, Sandoz, a Swiss-based pharmaceutical company, introduced a generic version of pirfenidone, the first AB-rated equivalent to Genentech's Esbriet, for treating idiopathic pulmonary fibrosis. This generic medication, accessible through specialty pharmacies, offers eligible patients the benefit of a USD 0 co-pay program.
Companies in the idiopathic pulmonary fibrosis market are directing their efforts toward innovative products such as anti-fibrotic small-molecule inhibitors to sustain their market positions. These inhibitors, designed to target and inhibit fibrotic processes in the body, represent a significant advancement. In June 2023, Insilico Medicine, a US-based biotechnology company, initiated Phase II clinical trials for INS018_055, the world's first anti-fibrotic small molecule inhibitor designed through generative artificial intelligence. This groundbreaking approach utilizing AI in drug discovery showcases the potential for progress in idiopathic pulmonary fibrosis treatment.
In October 2022, AbbVie Inc., a US-based pharmaceutical company, acquired DJS Antibodies Ltd., a UK-based biotechnology company specializing in the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. This acquisition aims to enhance AbbVie's antibody research capabilities and expand its immunology portfolio.
Major companies operating in the idiopathic pulmonary fibrosis market include F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Gilead Sciences Inc., Toray Industries Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Inc., Zydus Lifesciences Ltd., Chong Kun Dang Pharmaceutical Corp., Kyorin Pharmaceutical Co. Ltd., Galapagos NV, Veracyte Inc., Genentech Inc., FibroGen Inc., GNI Group Ltd., Pliant Therapeutics Inc., Pulmatrix Inc., Galimedix Therapeutics Inc., Avalyn Pharma Inc., MediciNova Inc., Liminal BioSciences Inc., Beijing Continent Pharmaceuticals Company, Galecto Inc.
North America was the largest region in the idiopathic pulmonary fibrosis market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic pulmonary fibrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the idiopathic pulmonary fibrosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
Idiopathic pulmonary fibrosis (IPF) is a lung disease characterized by the gradual and continuous deterioration of the tissue surrounding the air sacs, known as alveoli, in the lungs. This condition results in the accumulation of scar tissue (fibrosis) within the lungs, hindering the efficient transfer of oxygen into the bloodstream.
The main types of drugs used in the treatment of idiopathic pulmonary fibrosis include nintedanib, pirfenidone, and others. Nintedanib is a medication prescribed for the treatment of specific lung conditions, including idiopathic pulmonary fibrosis (IPF), which is an interstitial lung disease with a progressive phenotype, and interstitial lung disease associated with systemic sclerosis. These drugs operate through various modes of action, such as antifibrotic agents and tyrosine kinase inhibitors, and can be administered through various routes, including oral and parenteral. Distribution channels for these medications include hospital pharmacies, retail pharmacies, and online platforms, serving various end users such as hospitals, clinics, and others.
The idiopathic pulmonary fibrosis market research report is one of a series of new reports that provides idiopathic pulmonary fibrosis market statistics, including idiopathic pulmonary fibrosis industry global market size, regional shares, competitors with idiopathic pulmonary fibrosis market share, detailed idiopathic pulmonary fibrosis market segments, market trends, and opportunities, and any further data you may need to thrive in the idiopathic pulmonary fibrosis industry. This idiopathic pulmonary fibrosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The idiopathic pulmonary fibrosis (IPF) market consists of sales of anti-inflammatory, MAPK inhibitors, autotoxin inhibitors and corticosteroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The idiopathic pulmonary fibrosis market size is expected to see strong growth in the next few years. It will grow to $5.74 billion in 2029 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to expanded research and development, precision medicine approach, increasing disease incidence, advancements in biomarker development, government initiatives and funding. Major trends in the forecast period include advancements in diagnostic techniques, emergence of targeted therapies, telemedicine and remote monitoring, combination therapies, advancements in lung transplantation.
The idiopathic pulmonary fibrosis market is poised for growth, primarily driven by the increasing prevalence of fibrotic diseases. These conditions, marked by the abnormal accumulation of fibrous connective tissue in various organs, receive treatment through idiopathic pulmonary fibrosis (IPF) drugs targeting fibrosis-related signaling pathways. Notably, the American Lung Association reported in December 2022 that around 207,000 individuals in the United States were affected, with approximately 58,000 new IPF cases diagnosed annually. This condition, more prevalent in men and predominantly affecting those aged over 50, underscores the significant role of escalating fibrotic diseases in driving the idiopathic pulmonary fibrosis market.
The growing geriatric population is anticipated to drive the expansion of the idiopathic pulmonary fibrosis (IPF) market in the future. The geriatric population consists of elderly individuals within a specific society or community. Aging is linked to both structural and functional changes in the lungs, which increase the vulnerability of older adults to respiratory diseases like IPF. This age-related susceptibility contributes to the rising demand for IPF treatments. For example, in October 2022, the World Health Organization, a specialized health agency based in the US, reported that by 2030, 1 in 6 people globally will be aged 60 or older, with the number of individuals in this age group expected to reach 2.1 billion by 2050. Consequently, the increasing geriatric population is propelling the growth of the idiopathic pulmonary fibrosis market.
A notable trend gaining momentum in the idiopathic pulmonary fibrosis market is product innovation. Major companies in the industry are placing emphasis on developing innovative products to strengthen their market positions and gain a competitive advantage. For instance, in May 2022, Sandoz, a Swiss-based pharmaceutical company, introduced a generic version of pirfenidone, the first AB-rated equivalent to Genentech's Esbriet, for treating idiopathic pulmonary fibrosis. This generic medication, accessible through specialty pharmacies, offers eligible patients the benefit of a USD 0 co-pay program.
Companies in the idiopathic pulmonary fibrosis market are directing their efforts toward innovative products such as anti-fibrotic small-molecule inhibitors to sustain their market positions. These inhibitors, designed to target and inhibit fibrotic processes in the body, represent a significant advancement. In June 2023, Insilico Medicine, a US-based biotechnology company, initiated Phase II clinical trials for INS018_055, the world's first anti-fibrotic small molecule inhibitor designed through generative artificial intelligence. This groundbreaking approach utilizing AI in drug discovery showcases the potential for progress in idiopathic pulmonary fibrosis treatment.
In October 2022, AbbVie Inc., a US-based pharmaceutical company, acquired DJS Antibodies Ltd., a UK-based biotechnology company specializing in the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. This acquisition aims to enhance AbbVie's antibody research capabilities and expand its immunology portfolio.
Major companies operating in the idiopathic pulmonary fibrosis market include F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Gilead Sciences Inc., Toray Industries Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Inc., Zydus Lifesciences Ltd., Chong Kun Dang Pharmaceutical Corp., Kyorin Pharmaceutical Co. Ltd., Galapagos NV, Veracyte Inc., Genentech Inc., FibroGen Inc., GNI Group Ltd., Pliant Therapeutics Inc., Pulmatrix Inc., Galimedix Therapeutics Inc., Avalyn Pharma Inc., MediciNova Inc., Liminal BioSciences Inc., Beijing Continent Pharmaceuticals Company, Galecto Inc.
North America was the largest region in the idiopathic pulmonary fibrosis market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic pulmonary fibrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the idiopathic pulmonary fibrosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
Idiopathic pulmonary fibrosis (IPF) is a lung disease characterized by the gradual and continuous deterioration of the tissue surrounding the air sacs, known as alveoli, in the lungs. This condition results in the accumulation of scar tissue (fibrosis) within the lungs, hindering the efficient transfer of oxygen into the bloodstream.
The main types of drugs used in the treatment of idiopathic pulmonary fibrosis include nintedanib, pirfenidone, and others. Nintedanib is a medication prescribed for the treatment of specific lung conditions, including idiopathic pulmonary fibrosis (IPF), which is an interstitial lung disease with a progressive phenotype, and interstitial lung disease associated with systemic sclerosis. These drugs operate through various modes of action, such as antifibrotic agents and tyrosine kinase inhibitors, and can be administered through various routes, including oral and parenteral. Distribution channels for these medications include hospital pharmacies, retail pharmacies, and online platforms, serving various end users such as hospitals, clinics, and others.
The idiopathic pulmonary fibrosis market research report is one of a series of new reports that provides idiopathic pulmonary fibrosis market statistics, including idiopathic pulmonary fibrosis industry global market size, regional shares, competitors with idiopathic pulmonary fibrosis market share, detailed idiopathic pulmonary fibrosis market segments, market trends, and opportunities, and any further data you may need to thrive in the idiopathic pulmonary fibrosis industry. This idiopathic pulmonary fibrosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The idiopathic pulmonary fibrosis (IPF) market consists of sales of anti-inflammatory, MAPK inhibitors, autotoxin inhibitors and corticosteroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Idiopathic Pulmonary Fibrosis Market Characteristics3. Idiopathic Pulmonary Fibrosis Market Trends and Strategies4. Idiopathic Pulmonary Fibrosis Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global Idiopathic Pulmonary Fibrosis Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Idiopathic Pulmonary Fibrosis Market34. Recent Developments in the Idiopathic Pulmonary Fibrosis Market
5. Global Idiopathic Pulmonary Fibrosis Growth Analysis and Strategic Analysis Framework
6. Idiopathic Pulmonary Fibrosis Market Segmentation
7. Idiopathic Pulmonary Fibrosis Market Regional and Country Analysis
8. Asia-Pacific Idiopathic Pulmonary Fibrosis Market
9. China Idiopathic Pulmonary Fibrosis Market
10. India Idiopathic Pulmonary Fibrosis Market
11. Japan Idiopathic Pulmonary Fibrosis Market
12. Australia Idiopathic Pulmonary Fibrosis Market
13. Indonesia Idiopathic Pulmonary Fibrosis Market
14. South Korea Idiopathic Pulmonary Fibrosis Market
15. Western Europe Idiopathic Pulmonary Fibrosis Market
16. UK Idiopathic Pulmonary Fibrosis Market
17. Germany Idiopathic Pulmonary Fibrosis Market
18. France Idiopathic Pulmonary Fibrosis Market
19. Italy Idiopathic Pulmonary Fibrosis Market
20. Spain Idiopathic Pulmonary Fibrosis Market
21. Eastern Europe Idiopathic Pulmonary Fibrosis Market
22. Russia Idiopathic Pulmonary Fibrosis Market
23. North America Idiopathic Pulmonary Fibrosis Market
24. USA Idiopathic Pulmonary Fibrosis Market
25. Canada Idiopathic Pulmonary Fibrosis Market
26. South America Idiopathic Pulmonary Fibrosis Market
27. Brazil Idiopathic Pulmonary Fibrosis Market
28. Middle East Idiopathic Pulmonary Fibrosis Market
29. Africa Idiopathic Pulmonary Fibrosis Market
30. Idiopathic Pulmonary Fibrosis Market Competitive Landscape and Company Profiles
31. Idiopathic Pulmonary Fibrosis Market Other Major and Innovative Companies
35. Idiopathic Pulmonary Fibrosis Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Idiopathic Pulmonary Fibrosis Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on idiopathic pulmonary fibrosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for idiopathic pulmonary fibrosis? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The idiopathic pulmonary fibrosis market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Drug Type: Nintedanib; Pirfenidone; Other Drug Types2) By Mode of Action: Antifibrotic Agents; Tyrosine Kinase Inhibitors; Other Modes of Action
3) By Route of Administration: Oral; Parenteral
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Providers
5) By End Users: Hospitals and Clinics; Other End Users
Subsegments:
1) By Nintedanib: Indications; Dosage Forms; Administration Routes2) By Pirfenidone: Indications; Dosage Forms; Administration Routes
3) By Other Drug Types: Specific Agents or Classes; Emerging Therapies; Combination Therapies
Key Companies Mentioned: F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG; Bristol-Myers Squibb Company; AstraZeneca PLC
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Novartis AG
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- Sanofi S.A.
- Gilead Sciences Inc.
- Toray Industries Inc.
- Boehringer Ingelheim International GmbH
- Viatris Inc.
- Sun Pharmaceutical Industries Limited
- Shionogi and Co. Ltd.
- Cipla Inc.
- Zydus Lifesciences Ltd.
- Chong Kun Dang Pharmaceutical Corp.
- Kyorin Pharmaceutical Co. Ltd.
- Galapagos NV
- Veracyte Inc.
- Genentech Inc.
- FibroGen Inc.
- GNI Group Ltd.
- Pliant Therapeutics Inc.
- Pulmatrix Inc.
- Galimedix Therapeutics Inc.
- Avalyn Pharma Inc.
- MediciNova Inc.
- Liminal BioSciences Inc.
- Beijing Continent Pharmaceuticals Company
- Galecto Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 4.39 Billion |
| Forecasted Market Value ( USD | $ 5.74 Billion |
| Compound Annual Growth Rate | 7.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 29 |
